I think for a lot of people and a lot of the calls that I take, it’s first of all actually receiving the correct diagnosis, because we have a lot of percentage rates of dementia diagnosis, but for us it’s about the quality of diagnosis, and research shows that a lot of people either don’t receive that diagnosis of dementia with Lewy bodies or are misdiagnosed. So I think that’s one of the really important things...
I think for a lot of people and a lot of the calls that I take, it’s first of all actually receiving the correct diagnosis, because we have a lot of percentage rates of dementia diagnosis, but for us it’s about the quality of diagnosis, and research shows that a lot of people either don’t receive that diagnosis of dementia with Lewy bodies or are misdiagnosed. So I think that’s one of the really important things. And secondly, my father lived with dementia with Lewy bodies. And I think the fact that there is no specific drug currently for people who fall into this category, and especially for those people that have other comorbidities as well, and because those people are very sensitive to drugs, or can be, something as exciting as this is really good, because at the moment we people get given a generic dementia drug or something that is for Alzheimer’s or something that is for Parkinson’s. And for a lot of people, those drugs make the symptoms worse. This milestone is huge, I think, for us, because earlier this year, I was attending the NICE conference in Manchester, and this passport and this route to clinical trials was discussed at the NICE conference, and more information was given, so to be told that this was going to happen, and for the number of calls, like last year, for example, I took 1000 calls from people living with the diagnosis and the family carers. And we have so many people that are desperate to take part in research. This is just phenomenal. I think it’s really important, it’s a key clinical piece for management going forward, because at the moment it’s really trying to find what drugs work for people, what people can tolerate, what dosages people can tolerate, to have a drug that is very, very specific for dementia with Lewy bodies, it’s just something that we haven’t had before in the field. And I think that this will be so vital for doctors going forward to be able to recommend that people try this drug.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
